Our main findings indicate that including TP53 in routine genetic testing of HBOC Brazilian patients might be worthwhile, and that familial history of cancer might outperform risk prediction models in predicting PV/LPV carriers, at least for BRCA2. This evidence concerns the gene BRCA2 and cancer.